Condition (MeSH)
Entropion
ClinicalTrials.gov lists 15 trials for Entropion or a narrower condition beneath it. Alcon Research has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
15 of the 15 trials are tagged with Entropion itself; the rest are tagged with a narrower condition beneath it.
When did Entropion trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 2 |
| 2018 | 1 |
| 2016 | 3 |
| 2010 | 1 |
| 2007 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Entropion trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 4 | 3 |
| Not applicable | 9 |
| Observational | 3 |
How many Entropion trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 7 |
| Suspended | 1 |
| Withdrawn | 2 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Entropion trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Alcon Research | 2 |
| Aesculap AG | 1 |
Which drugs are being tested for Entropion? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Desflurane | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Sevoflurane | 1 |
| Suture | 1 |
| Brimonidine Topical | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Entropion? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Eyelash line resection for cilial entropion in patients with Down's syndrome. | The British journal of ophthalmology | 2014 | Yes |
| Ocular surface reconstruction using the combination of autologous cultivated oral mucosal epithelial transplantation and eyelid surgery for severe ocular surface disease. | American journal of ophthalmology | 2011 | Yes |
| Characteristics of trichiasis patients presenting for surgery in rural Ethiopia. | The British journal of ophthalmology | 2005 | Yes |
| Botulinum toxin for the treatment of congenital entropion. | American journal of ophthalmology | 2004 | Yes |
| Amniotic membrane transplantation for ocular surface reconstruction in Stevens-Johnson syndrome. | Ophthalmology | 2000 | Yes |
Showing 5 of 7 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.